People with Cystic Fibrosis (CF) are living longer and healthier lives due in part to new therapies, called Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulators. However, disparities in outcomes still exist, with females demonstrating a shorter life expectancy than males; this is opposed to the typical female versus male life expectancy in the general United States population. In addition, minority populations such as those of Hispanic ethnicity and African Americans are less frequently eligible for these new CFTR modulators. The mechanisms driving this difference and the relative contribution of CFTR to the etiology are not yet elucidated.
Keywords: Cystic fibrosis; Cystic fibrosis transmembrane conductance regulator (CFTR) modulators; Estrogen; Gonadal hormones; Racial disparities; Sex disparity.
Copyright © 2022 Elsevier Inc. All rights reserved.